Ticker Launch
Sign inTry it free

SPAC · Deal announced · BKHA

Black Hawk Acquisition Corp

Business combination with Vesicor Therapeutics, Inc.

Black Hawk Acquisition Corp (BKHA) is a blank-check company (SPAC) that raised $69M in its initial public offering on Mar 22, 2024, listing on Nasdaq Global Market. It agreed to combine with Vesicor Therapeutics, Inc., announced on Apr 29, 2025. The deal has not closed yet. EF Hutton led the IPO. Ogier advised the SPAC and Robinson & Cole advised the underwriters on the IPO.

Vesicor Therapeutics, Inc. is a California-based, early development stage biotechnology company developing p53-based cancer therapeutics delivered through precision-engineered microvesicles. It signed a business combination agreement with Black Hawk Acquisition in April 2025.

Status
Deal announced
Ticker
BKHA
IPO date
Mar 22, 2024
IPO size
$69M
IPO exchange
Nasdaq Global Market
Target
Vesicor Therapeutics, Inc.
Target sector
Biotech
Announced
Apr 29, 2025
Combined company
Vesicor Therapeutics Holdings, Inc.
IPO underwriters
EF Hutton
SPAC counsel (IPO)
Ogier
Underwriters' counsel (IPO)
Robinson & Cole

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other pending SPAC mergers